COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?
Open accessAbstract
The SARS-CoV-2 pandemic is a global health emergency and we need to know more about it. Patients with cardiovascular risk and previous kidney risk have been identified as especially vulnerable for greater morbidity and mortality when they suffer from COVID-19. A considerable proportion of patients can develop a vascular lesion in the context of the disease that entails a greater lethality. Cardiovascular and renal complications represent a problem and, probably in the near future, may pose a threat to patients who have survived COVID-19. As physicians, we cannot forget that during an epidemic like this, other chronic diseases are present, and patients continue to require care. We are obliged to monitor even more intensely their treatments and control degree. Furthermore, we must not forget that urgent situations continue to arise in this pandemic situation and require prompt attention. In this current situation, it is very likely that many patients, out of fear, have not sought medical attention. The situation during the epidemic and the uncertainty of the post-COVID-19 period, requires intensification in the control and monitoring of cardiovascular and kidney disease in our patients. Primary care constitutes a key level of care for the care of the population with cardiovascular disease. Likewise, and in the face of this new health scenario, we need to promote the prevention and control measures that emanate from the studies currently underway. Now, more than ever, we need research, crucial to improve the cardiovascular and renal prognosis of our patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Having preexisting diseases, together with fear of COVID-19, is considered a risk factor for complications or severity of COVID-19, which in turn would increase the risk of depressive symptoms.
“Tener enfermedades preexistentes, sumado con el miedo a la COVID-19, es considerado como factor de riesgo para complicaciones o severidad de la enfermedad por COVID-1921, lo cual traería consigo a su vez mayor riesgo de presentar síntomas depresivos22.”
From Síntomas depresivos en trabajadores de la salud dos años después del inicio de la pandemia COVID-19 en Bogotá, Colombia (2025) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · see citing works
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415 · see citing works
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148 · see citing works
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463 · see citing works
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016 · see citing works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140 · see citing works
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · see citing works
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358 · see citing works
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187 · see citing works
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898 · see citing works
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · see citing works
COVID-19 and the cardiovascular system
Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., & Xie, X. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0360-5 · Cited by 2,970 · see citing works
Kidney disease is associated with in-hospital death of patients with COVID-19
Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., Li, J., Yao, Y., Ge, S., & Xu, G. (2020) · Kidney International · doi:10.1016/j.kint.2020.03.005 · Cited by 2,957 · see citing works
Zou, X., Chen, K., Zou, J., Han, P., Hao, J., & Han, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0754-0 · Cited by 2,287 · see citing works
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101 · see citing works
Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China
Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., Bi, Z., & Zhao, Y. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01626-9 · Cited by 2,052 · see citing works
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)
Inciardi, R. M., Lupi, L., Zaccone, G., Italia, L., Raffo, M., Tomasoni, D., Cani, D., Cerini, M., Farina, D., Gavazzi, E., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1096 · Cited by 1,860 · see citing works
Ferrario, C. M., Jessup, J. A., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,567 · see citing works
Viral load of SARS-CoV-2 in clinical samples.
Pan, Y., Zhang, D., Yang, P., Poon, L. L. M., & Wang, Q. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30113-4 · Cited by 1,562 · see citing works
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow, N. A., Fleming-Dutra, K. E., Gierke, R., Hall, A. J., Hughes, M. M., Pilishvili, T., Ritchey, M. D., Roguski, K. M., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6913e2 · Cited by 1,399 · see citing works
Can we contain the COVID-19 outbreak with the same measures as for SARS?
Wilder‐Smith, A., Chiew, C. J., & Lee, V. J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30129-8 · Cited by 961 · see citing works
Clinical Features of COVID-19-Related Liver Functional Abnormality
Fan, Z., Chen, L., Li, J., Cheng, X., Yang, J., Tian, C., Zhang, Y., Huang, S., Liu, Z., & Cheng, J. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.002 · Cited by 949 · see citing works
Tam, C. C., Cheung, K., Lam, S. C. C., Wong, Y. T. A., Yung, A. S. Y., Sze, M., Lam, Y., Chan, C., Tsang, T.-C., Tsui, M., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006631 · Cited by 944 · see citing works
Akhmerov, A., & Marbán, E. (2020) · Circulation Research · doi:10.1161/circresaha.120.317055 · Cited by 694 · see citing works
Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection
Henry, B. M., & Lippi, G. (2020) · International Urology and Nephrology · doi:10.1007/s11255-020-02451-9 · Cited by 543 · see citing works
Li, J., Wang, X., Chen, J., Zhang, H., & Deng, A. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1624 · Cited by 537 · see citing works
Renin-Angiotensin System Blockers and the COVID-19 Pandemic
Danser, A. H. J., Epstein, M., & BATLLE, D. C. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15082 · Cited by 457 · see citing works
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452 · see citing works
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
Kuster, G. M., Pfister, O., Burkard, T., Zhou, Q., Twerenbold, R., Haaf, P., Widmer, A. F., & Osswald, S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa235 · Cited by 395 · see citing works
Goldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354 · see citing works
COVID-19 and diabetes: Can DPP4 inhibition play a role?
Iacobellis, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108125 · Cited by 320 · see citing works
Kidney impairment is associated with in-hospital death of COVID-19 patientsPreprint
Cheng, Y., Luo, R., Wang, K., et al. (2020) · medRxiv · doi:10.1101/2020.02.18.20023242 · Cited by 301 · see citing works
Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042007 · Cited by 291 · see citing works
Deshotels, M. R., Xia, H., Sriramula, S., Lazartigues, E. D., & Filipeanu, C. M. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03743 · Cited by 264 · see citing works
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
Sun, M. L., Yang, J. M., Sun, Y., & Su, G. (2020) · PubMed · doi:10.3760/cma.j.issn.1001-0939.2020.0014 · Cited by 228 · see citing works
Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
Oliva, R., & Bakris, G. L. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.02.003 · Cited by 218 · see citing works
Rodríguez‐Leor, O., Cid-Álvarez, B. A., Ojeda, S., et al. (2020) · REC, Interventional cardiology · doi:10.24875/recic.m20000120 · Cited by 179 · see citing works
Clinical Features of COVID-19-Related Liver DamagePreprint
Fan, Z., Chen, L., Li, J., et al. (2020) · medRxiv · doi:10.1101/2020.02.26.20026971 · Cited by 165 · see citing works
Larsen, J. M., & Ravkilde, J. (2012) · Resuscitation · doi:10.1016/j.resuscitation.2012.08.337 · Cited by 162 · see citing works
Considerations for Statin Therapy in Patients with COVID‐19
Dashti‐Khavidaki, S., & Khalili, H. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2397 · Cited by 103 · see citing works
Escobar, C., Anguita, M. P., Arrarte, V., Barrios, V., Cequier, A. R., Cosı́n-Sales, J., Egocheaga, I., de Sá, E. L., Masana, L., Pallarés‐Carratalá, V., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.07.024 · Cited by 63 · see citing works
Self-citationAcanfora, D., Ciccone, M. M., Scicchitano, P., Acanfora, C., & Casucci, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa028 · Cited by 52 · see citing works
Statins in coronavirus outbreak: It’s time for experimental and clinical studies
Bifulco, M., & Gazzerro, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104803 · Cited by 38 · see citing works
The Effect of Weight Loss in Obesity and Chronic Kidney Disease
Morales, E., & Praga, M. (2012) · Current Hypertension Reports · doi:10.1007/s11906-012-0247-x · Cited by 36 · see citing works
Cinza‐Sanjurjo, S., Prieto-Díaz, M. Á., Caro, J. L. L., Barquilla-García, A., Padial, L. R., Vidal-Pérez, R., Roca, G. C. R., Maestro, J. J. B., & Pallarés‐Carratalá, V. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2018.11.003 · Cited by 26 · see citing works
Self-citationRecommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology
Escobar, C., Anguita, M. P., Arrarte, V., Barrios, V., Cequier, A. R., Cosı́n-Sales, J., Egocheaga, I., de Sá, E. L., Masana, L., Pallarés‐Carratalá, V., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.08.012 · Cited by 22 · see citing works
Self-citationInteracciones graves o potencialmente letales entre antirretrovirales y otros medicamentos
Manzardo, C., Tuset, M., Miró, J. M., & Gatell, J. M. (2014) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2014.02.020 · Cited by 13 · see citing works
Redondo, E., Calle, I. R., Vargas, D., et al. (2016) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2016.07.009 · Cited by 13 · see citing works
Documento de consenso SEA/SEMERGEN 2019. Recomendaciones dietéticas en la prevención cardiovascular
Pascual, V., Pérez‐Martínez, P., Fernández, J. M., Solà, R., Pallarés‐Carratalá, V., Secin, A. A. R., Jiménez, F. P., & Ros, E. (2019) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2019.02.015 · Cited by 12 · see citing works
Self-citationLa maldita pandemia: una oportunidad para la Atención Primaria de Salud
Caro, J. L. L. (2020) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2020.03.001 · Cited by 8 · see citing works
Romero-Vigara, J. C., Caro, J. L. L., Turégano-Yedro, M., Cinza‐Sanjurjo, S., González, L. M., Silvero, Y. A., Segura‐Fragoso, A., Patiño, J. S., García, J. I., & Rivero, J. B. (2018) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2018.10.004 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Noguera Novoa, C. N., Sarmiento-Melendez, Y. T., Sierra-Hincapié, G. M., & González-Díaz, J. M. (2025) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2023.04.006 · Cited by 5 · see citing works
- Authors
- Pallarés Carratalá, V., Górriz-Zambrano, C., Morillas Ariño, C., Llisterri Caro, J. L., & Gorriz, J. L.
- Venue
- Medicina de Familia. SEMERGEN
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 46
- Pages
- 78-87
- ISSN
- 1138-3593 (ISSN-L)
- PMC
- PMC7211659
- OpenAlex
- W3021622479
- Cited by
- 21
- References
- 54
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 1
- FWCI
- 0.20
- Type
- journal article
- Language
- es
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Medicina de Familia SEMERGEN (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Repositori UJI (Universitat Jaume I) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
- Keywords
- COVID-19 pandemic, SARS-CoV-2, cardiovascular disease, chronic kidney disease, comorbidities, cardiovascular complications, renal complications, primary care, disease surveillance, delayed care seeking, prevention
- MeSH terms
- COVID-19, Cardiovascular Diseases, Humans, Kidney Diseases, Pneumonia, Viral, Risk Factors, Coronavirus Infections, Diabetes Complications, Dyslipidemias, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
